Category: Regulatory

Minnesota Issues Draft Guidance Implementing 340B Provider Reporting Requirements

December 14, 2023 Views

The Minnesota Department of Health finalized guidance for the state's new annual 340B covered entity reporting requirements.

Stakeholder comments are due Tuesday on Minnesota’s recently published guidance to implement one of the nation’s first state laws requiring [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Michigan to Increase Medicaid Payment for 340B Hospitals, Adds Reporting Requirements

December 14, 2023 Views

The Michigan Department of Health and Human Services released a new 340B hospital billing and reporting rule.

At the start of 2024, Michigan 340B hospitals can bill the state at higher payment rates for outpatient drugs; later [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Novo Nordisk to Provide 340B Refunds on Hemophilia Drugs

December 14, 2023 Views

Novo Nordisk will issue 340B provider refunds for formulations of two hemophilia drugs, according to a HRSA manufacturer notice.

Novo Nordisk will issue its fifth round of refunds this year on prices charged to 340B providers. The latest are [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Federal 340B Leader Moves On After 21 Months

December 7, 2023 Views

U.S. Public Health Service Lieutenant Commander Emeka Egwim left his position as director of OPA at HRSA 21 months after he started.

U.S. Public Health Service Lieutenant Commander Emeka Egwim left his position as director of the federal office overseeing the 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Amid Record Drugmaker Refunds, No Adverse Audit Findings for Teva

December 7, 2023 Views

The final HRSA manufacturer 340B program audit conducted in fiscal year 2023 had no adverse findings for Teva Pharmaceuticals.

The fifth and final fiscal year 2023 manufacturer audit by federal officials recently concluded with no adverse findings. Meanwhile, the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

New Part B Drug Claims Modifier Requirement for 340B Entities Starts Jan. 1

December 7, 2023 Views

In response to the ongoing Change Healthcare cyberattack, CMS will direct contractors to provide some accelerated payments to hospitals.

Critical access hospitals (CAHs) and Ryan White HIV/AIDS clinics do not expect problems implementing a new requirement starting Jan. 1, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Four 340B Terminations, Eight Paybacks to Manufacturers in Latest Provider Audit Findings

December 5, 2023 Views

Federal auditors determined terminations from the 340B program were required for either covered entity sites or a contract pharmacy of two more 340B providers.

Federal auditors determined terminations from the 340B program were required for either covered entity sites or contract pharmacies of four [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

N.Y. State, Health Centers Seek Brief Pause in Medicaid Drug Benefit Lawsuit

November 30, 2023 Views

The parties involved in a legal challenge over certain Medicaid managed care drug benefits have jointly asked for a pause in proceedings.

Both sides in a lawsuit over New York state’s transfer of Medicaid managed care drug benefits to Medicaid fee for [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Provides Benefits, Needs Reform, Says Literature Review

November 28, 2023 Views

A JAMA Health Network literature review found that the 340B program provides a range of benefits but needs reforms.

The 340B program has provided a range of benefits but also needs reforms, according to a recent review of published [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Two Drugmakers Offer Refunds for 340B Overcharges

November 28, 2023 Views

Two drugmakers, Mallinckrodt's subsidiary SpecGx and Novo Nordisk, owe refunds to 340B providers for certain overcharges.

Two drugmakers will offer refunds to 340B providers for overcharges in recent years. Drug manufacturer Mallinckrodt’s SpecGx generic pharmaceutical subsidiary [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Exclusive

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a